Evidence map›Paper›PMID 39386567›Full record

ArticlebioRxiv : the preprint server for biology2024

Dynamics of Spike-Specific Neutralizing Antibodies Across Five-Year Emerging SARS-CoV-2 Variants of Concern Reveal Conserved Epitopes that Protect Against Severe COVID-19.

Latifa Zayou, Swayam Prakash, Hawa Vahed, Nisha Rajeswari Dhanushkodi, Afshana Quadiri, Ahmed Belmouden, Zohra Lemkhente, Aziz Chentoufi, Daniel Gil, Jeffrey B Ulmer and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Latifa ZayouLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.
Swayam PrakashLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.
Hawa VahedDepartment of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, CA 92660; USA.
Nisha Rajeswari DhanushkodiLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.
Afshana QuadiriLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.
Ahmed BelmoudenLaboratory of Cell Biology and Molecular Genetics, Faculty of Sciences, Ibn Zohr University, Agadir, Morocco.
Zohra LemkhenteLaboratory of Medical-Surgical, Biomedicine and infectiology Research, Faculty of Medicine and Pharmacy, Ibnou Zohr University, Agadir, Morocco.
Aziz ChentoufiLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.
Daniel GilDepartment of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, CA 92660; USA.
Jeffrey B UlmerDepartment of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, CA 92660; USA.
Lbachir BenMohamedLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697.

Funding

A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital HerpesR01AI150091 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Lbachir BenMohamed · 2020 to 2026
$4.0M
Developing a Multi-epitope Pan-Coronavirus VaccineR01AI158060 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2020 to 2024
$3.7M
Mucosal Chemokines and CD8+ T Cell Immunity to Genital HerpesR01AI143348 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2022
$2.4M
A Novel Multi-Epitope-Based Universal Vaccine Against Multiple Coronavirus Variants of ConcernR43AI174383 · NIAID · TECHIMMUNE, LLC · PI VAHED, HAWA · 2023 to 2024
$600k
Impact of Immune Checkpoints Blockade on HSV-1 Neuro-PathogenesisR21AI143326 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$464k
LAT-HVEM Interactions Effect HSV-1 Latency/ReactivationR21AI110902 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2015 to 2016
$425k
PROTECTIVE IMMUNITY AGAINST RECURRENT OCULAR HERPES INDUCED WITH SELF-ASSEMBLING PROTEIN NANOPARTICLESR21AI147499 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$399k
A NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINER41AI138764 · NIAID · SUNOMIX THERAPEUTICS · PI BENMOHAMED, LBACHIR · 2018 to 2018
$236k
A NOVEL IMMUNO-PROTEOMIC APPROACH TO A GENITAL HERPES VACCINER43AI124911 · NIAID · IMMPORT THERAPEUTICS, INC. · PI LIANG, XIAOWU · 2016 to 2016
$225k
NIAID NIH HHS R01 AI143348NIAID NIH HHS R01 AI150091NIAID NIH HHS R01 AI158060NIAID NIH HHS R21 AI110902NIAID NIH HHS R21 AI143326NIAID NIH HHS R21 AI147499NIAID NIH HHS R41 AI138764NIAID NIH HHS R43 AI124911NIAID NIH HHS R43 AI174383
6 · The paper itself

Abstract

Since early 2020, several SARS-CoV-2 variants of concern (VOCs) continue to emerge, evading waning antibody mediated immunity produced by the current Spike-alone based COVID-19 vaccines. This caused a prolonged and persistent COVID-19 pandemic that is going to enter its fifth year. Thus, the need remains for innovative next generation vaccines that would incorporate protective Spike-derived B-cell epitopes that resist immune evasion. Towards that goal, in this study we (

Indexed as

AgeAntibodiesB cell epitopesCOVID-19Disease SeverityGenderSARS-CoV-2

Identifiers

PMID39386567
PMCPMC11463540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.